1 / 28

Symplicity HTN-1: 36-mo Follow-up Sustained Reductions in BP

Thank you for taking the preassessment. (Note: the questions were developed by an independent consulting group with expertise in assessing the effectiveness of medical education.) To assess learning, these questions will be repeated at the end of the activity.

darius-maynard
Download Presentation

Symplicity HTN-1: 36-mo Follow-up Sustained Reductions in BP

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Thank you for taking the preassessment. (Note: the questions were developed by an independent consulting group with expertise in assessing the effectiveness of medical education.)To assess learning, these questions will be repeated at the end of the activity.

  2. Symplicity HTN-1: 36-mo Follow-upSustained Reductions in BP

  3. “Pleiotropic” Non-BP-Lowering Effects of Renal Denervation

  4. ALSTER BP Registry: Efficacy and Safety of Redo Renal Denervation in Nonresponders

  5. Renal Artery Stenosis After Renal Denervation

  6. Case Reports of Renal Artery Stenosis After Renal Denervation

  7. Symplicity HTN-1: eGFR Stable So Far

  8. Urinary Albumin Excretion

  9. EnligHTN First in Man: Renal Function

  10. Surrogates of Vascular Stiffness Reduced With Renal Denervation

  11. Small Reductions in BP Lower Stroke/IHD Mortality

  12. EnligHTNment Trial (Design Not Finalized)

  13. European Society of Cardiology Consensus: Eligibility

  14. Multidisciplinary Team Considerations

  15. Avoid RDN in Stented Renal Arteries

  16. Symplicity Spyral First in Man

  17. Symplicty Global Registry (149 Sites)

  18. Abbreviations

  19. References

  20. References (cont)

  21. References (cont)

  22. References (cont)

  23. References (cont)

More Related